Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391529 | 0.87 | PYGL (0.34) | MMEAGTR1 | |
| SCHEMBL3265454 | 0.84 | AGTR1 (0.39) | AGTR1 | |
| SCHEMBL2390851 | 0.79 | AGTR1 (0.41) | MMEAGTR1 | |
| SCHEMBL2390833 | 0.79 | AGTR1 (0.41) | MMEAGTR1 | |
| SCHEMBL2393563 | 0.78 | AGTR1 (0.40) | MMEAGTR1 | |
| SCHEMBL2392233 | 0.78 | AGTR1 (0.40) | MMEAGTR1 | |
| SCHEMBL2393132 | 0.78 | AGTR1 (0.37) | MMEAGTR1 | |
| SCHEMBL652532 | 0.78 | MME (0.40) | MMEAGTR1CTRB1 | |
| SCHEMBL2393584 | 0.78 | MMEL1 (0.45) | MMEAGTR1 | |
| SCHEMBL2392782 | 0.76 | AGTR1 (0.40) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 6/4885AGTR1 1/4885CTRB1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.